RS20090104A - Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors - Google Patents

Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors

Info

Publication number
RS20090104A
RS20090104A RSP-2009/0104A RSP20090104A RS20090104A RS 20090104 A RS20090104 A RS 20090104A RS P20090104 A RSP20090104 A RS P20090104A RS 20090104 A RS20090104 A RS 20090104A
Authority
RS
Serbia
Prior art keywords
inhibitors
pyrudo
pyrimidinone compounds
compounds
pyrimidinone
Prior art date
Application number
RSP-2009/0104A
Other languages
English (en)
Inventor
Mitchell David Nambu
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabet Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of RS20090104A publication Critical patent/RS20090104A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ovaj pronalazak se odnosi na nova 4-metilpiridopirimidinon jedinjenja Formule (I) i na njihove soli, njihovu sintezu i njihovu upotrebu kao inhibitora fosfoinozitid 3-kinaze alfa (PI3- Kα).
RSP-2009/0104A 2006-09-15 2007-09-03 Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors RS20090104A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (1)

Publication Number Publication Date
RS20090104A true RS20090104A (en) 2010-06-30

Family

ID=38859750

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20110379A RS51927B (sr) 2006-09-15 2007-09-03 Jedinjenja pirido (2,3-d)pirimidinona i njihova upotreba kao inhibitora p13
RSP-2009/0104A RS20090104A (en) 2006-09-15 2007-09-03 Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20110379A RS51927B (sr) 2006-09-15 2007-09-03 Jedinjenja pirido (2,3-d)pirimidinona i njihova upotreba kao inhibitora p13

Country Status (42)

Country Link
US (3) US7696213B2 (sr)
EP (1) EP2074122B9 (sr)
JP (1) JP4718637B2 (sr)
KR (1) KR101099926B1 (sr)
CN (1) CN101573358B (sr)
AP (1) AP2710A (sr)
AR (1) AR062785A1 (sr)
AT (1) ATE514695T1 (sr)
AU (1) AU2007297212B8 (sr)
BR (1) BRPI0716749B8 (sr)
CA (1) CA2663401C (sr)
CL (1) CL2007002682A1 (sr)
CR (1) CR10662A (sr)
CU (1) CU23783B7 (sr)
CY (1) CY1111911T1 (sr)
DK (1) DK2074122T5 (sr)
DO (1) DOP2009000039A (sr)
EA (1) EA016388B1 (sr)
ES (1) ES2366489T3 (sr)
GE (1) GEP20115306B (sr)
GT (1) GT200700077A (sr)
HK (1) HK1138589A1 (sr)
HN (1) HN2007000267A (sr)
HR (1) HRP20110621T2 (sr)
IL (1) IL197243A (sr)
MA (1) MA30709B1 (sr)
ME (1) MEP8009A (sr)
MX (1) MX2009002927A (sr)
MY (1) MY146420A (sr)
NI (1) NI200900032A (sr)
NO (1) NO342357B1 (sr)
NZ (1) NZ575167A (sr)
PE (1) PE20080670A1 (sr)
PL (1) PL2074122T3 (sr)
PT (1) PT2074122E (sr)
RS (2) RS51927B (sr)
SI (1) SI2074122T1 (sr)
TN (1) TN2009000085A1 (sr)
TW (1) TWI334353B (sr)
UY (1) UY30588A1 (sr)
WO (1) WO2008032162A1 (sr)
ZA (1) ZA200901477B (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663401C (en) 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
PL2139484T3 (pl) * 2007-04-10 2013-12-31 Exelixis Inc Sposoby leczenia raka z zastosowaniem pirydopirymidynonów jako inhibitorów PI3K alfa
CN101711249A (zh) * 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
MX2011000440A (es) * 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072939A1 (es) * 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
EP2331511A1 (en) 2008-08-20 2011-06-15 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
UY32153A (es) * 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
CN105859735B (zh) 2010-12-16 2018-03-09 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US9675595B2 (en) 2011-08-31 2017-06-13 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
WO2016055907A1 (en) 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
EP3636283A1 (en) 2015-06-04 2020-04-15 Pfizer Inc Solid dosage forms of palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2018009638A1 (en) 2016-07-06 2018-01-11 The Regents Of The University Of Michigan MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME
SI3497103T1 (sl) 2016-08-15 2021-07-30 Pfizer Inc. Zaviralci piridopirimdiona CDK2/4/6
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
EP3902801A4 (en) * 2018-12-28 2022-12-14 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.
CN114901664A (zh) * 2020-01-10 2022-08-12 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc GCN2 and PERK kinase inhibitors and methods of using them
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GEP20012444B (en) 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
IL150742A0 (en) 2000-01-27 2003-02-12 Warner Lambert Co Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
OA12227A (en) 2000-03-06 2004-03-18 Warner Lambert Co 5-AlkylpyridoÄ2,3-DÜpyrimidines tyrosine kinase inhibitors.
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
JP4166991B2 (ja) 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
CN102295643B (zh) 2002-01-22 2013-12-04 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
MXPA04010983A (es) 2002-05-06 2005-02-14 Genelabs Tech Inc Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
EP1624900A4 (en) 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
SI1648889T1 (sl) 2003-07-11 2009-02-28 Warner Lambert Co Izetionatna sol selektivnega CDK4 inhibitorja
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005080393A1 (en) 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2007530654A (ja) 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
CA2563669A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2005117980A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
DK1940839T3 (da) * 2005-10-07 2013-10-14 Exelixis Inc Pyridopyrimidione Inhibitors of P13Ka
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
CA2663401C (en) * 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
AU2008224941C1 (en) * 2007-03-14 2013-06-27 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
CN101711249A (zh) * 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
UY32153A (es) * 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
PL2074122T3 (pl) 2011-10-31
US20120309775A1 (en) 2012-12-06
KR20090040389A (ko) 2009-04-23
AP2009004790A0 (en) 2009-04-30
AP2710A (en) 2013-07-30
TW200820972A (en) 2008-05-16
US8633204B2 (en) 2014-01-21
EA200970207A1 (ru) 2009-08-28
HRP20110621T1 (en) 2011-09-30
CN101573358A (zh) 2009-11-04
NO342357B1 (no) 2018-05-14
GT200700077A (es) 2009-08-03
MY146420A (en) 2012-08-15
PT2074122E (pt) 2011-08-24
CN101573358B (zh) 2012-05-30
JP2010503653A (ja) 2010-02-04
SI2074122T1 (sl) 2011-10-28
NI200900032A (es) 2010-05-14
KR101099926B1 (ko) 2011-12-28
GEP20115306B (sr) 2011-10-10
CA2663401A1 (en) 2008-03-20
US8273755B2 (en) 2012-09-25
HK1138589A1 (en) 2010-08-27
DK2074122T5 (da) 2014-03-17
RS51927B (sr) 2012-02-29
US20100137279A1 (en) 2010-06-03
MA30709B1 (fr) 2009-09-01
AU2007297212B2 (en) 2011-04-14
IL197243A0 (en) 2009-12-24
CL2007002682A1 (es) 2008-04-04
MEP8009A (en) 2011-12-20
TN2009000085A1 (fr) 2010-08-19
BRPI0716749A2 (pt) 2014-02-18
NZ575167A (en) 2010-10-29
ES2366489T9 (es) 2013-12-27
ZA200901477B (en) 2010-07-28
EP2074122A1 (en) 2009-07-01
EA016388B1 (ru) 2012-04-30
IL197243A (en) 2013-07-31
CR10662A (es) 2009-04-17
DK2074122T3 (da) 2011-08-15
EP2074122B9 (en) 2013-09-11
WO2008032162A8 (en) 2009-03-26
CU20090040A7 (es) 2011-07-11
BRPI0716749B8 (pt) 2021-05-25
MX2009002927A (es) 2009-03-31
JP4718637B2 (ja) 2011-07-06
UY30588A1 (es) 2008-05-02
CY1111911T1 (el) 2015-11-04
EP2074122B1 (en) 2011-06-29
ATE514695T1 (de) 2011-07-15
TWI334353B (en) 2010-12-11
US7696213B2 (en) 2010-04-13
HRP20110621T2 (hr) 2013-12-06
PE20080670A1 (es) 2008-06-14
CU23783B7 (es) 2012-02-15
CA2663401C (en) 2011-07-12
US20080090801A1 (en) 2008-04-17
WO2008032162A1 (en) 2008-03-20
BRPI0716749B1 (pt) 2020-10-06
DOP2009000039A (es) 2015-12-15
AU2007297212B8 (en) 2011-04-28
HN2007000267A (es) 2011-02-25
NO20091141L (no) 2009-03-31
AR062785A1 (es) 2008-12-03
AU2007297212A1 (en) 2008-03-20
ES2366489T3 (es) 2011-10-20

Similar Documents

Publication Publication Date Title
RS20090104A (en) Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors
EA201000113A1 (ru) Пиразольные соединения
WO2007105058A3 (en) Pyrazole compounds
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GEP20135991B (en) 2-carboxamide-pyrrolidine-amide urea derivatives substituted with pyrimidine-4-yl, and usage thereat treatment of diseases caused by phosphatidyl inositol 3-kinase
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
HK1107984A1 (en) Pyrrolopyridine-2-carboxylic acid amide derivativeuseful as inhibitor of glycogen phosphorylase
MX2007001952A (es) Compuestos y composiciones utiles como inhibidores de catepsina-s.
UA93609C2 (en) 2-amino-5,6-dihydro-6h-pyrrolo[3, 4-d]pyrimidine derivatives as hsp-90 inhibitors for treating cancer
UA95113C2 (en) Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
ES2268990A1 (es) Compuestos quinonicos antitumorales y sus derivados, procedimiento de obtencion y sus aplicaciones.
MX2007015807A (es) Metodos de obtencion de fluorobencenamidas anticonvulsionantes.
HK1136288A1 (sr)